Exchange: NYSE·Updated 07:54 PM EDT

MCK News

News
all
press releases
Why Is McKesson (MCK) Up 5.7% Since Last Earnings Report?
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Zacks
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
Zacks
Here's Why McKesson (MCK) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks
Ex-Div Reminder for McKesson (MCK)
Looking at the universe of stocks we cover at Dividend Channel, on 9/1/26, McKesson Corp (Symbol: MCK) will trade ex-dividend, for its quarterly dividend of $0.94, payable on 10/1/26. As a percentage of MCK's recent stock price of $893.81, this dividend works out to approximate...
Nasdaq News: Markets
Here's How Much You Would Have Made Owning McKesson Stock In The Last 10 Years
McKesson (NYSE:MCK) has outperformed the market over the past 10 years by 3.54% on an annualized basis producing an average annual return of 17.04%. Currently, McKesson has a market capitalization of $103.82 billion.read more...
Benzinga
McKesson to Acquire Precision Medicine Group to Strengthen Services
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
Zacks
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
Zacks

Advertisement|Remove ads.